埃克替尼靶向治疗非小细胞肺癌效果及对患者EGFR、机体状态的影响

Efficacy of icotinib in the treatment of non-small cell lung cancer and its effect on EGFR and body condition in patients

目的探讨埃克替尼靶向治疗非小细胞肺癌效果及对患者EGFR、机体状态的影响。方法选取2012年7月~2015年7月在我院治疗的140例非小细胞肺癌患者随机分组,实验组患者应用埃克替尼联合吉西他滨、顺铂化疗,对照组患者给予吉西他滨联合顺铂化疗,观察比较两组患者治疗效果、免疫功能和营养状况差异。结果实验组患者近期治疗效果同对照组比较明显提高,免疫功能和营养状况显著改善,差异具有统计学意义(P<0.05)。结论针对非小细胞肺癌患者采用埃克替尼靶向治疗可提高治疗效果,改善免疫和营养功能,临床值得推广应用。

Objective To investigate the effect of icotinib on NSCLC patients and its effect on EGFR and body condition.Methods A total of140non-small cell lung cancer patients treated in Shenyang Tenth People's Hospital from July2012to July2015were randomly grouped.Patients in the experimental group were treated with icotinib combined with gemcitabine,cisplatin.The control group was given gemcitabine combined with cisplatin chemotherapy.The treatment effects,immune function and nutritional status differences between the two groups were observed and compared.Results The short-term treatment effect in the experimental group was significantly improved compared with that of the control group,and the immune function and nutritional status in the experimental group were significantly improved.The difference was statistically significant(P<0.05).Conclusion The targeted therapy of icotinib in patients with non-small cell lung cancer can improve the therapeutic effect,improve the immune and nutritional functions,and is worthy of applicaton in clinic.